West Sacramento, United States
Persist AI is positioning itself at the forefront of revolutionizing drug formulation, focusing on the significant challenge faced by pharmaceutical companies in the development of extended-release PLG drug formulations. Typically, this process demands over $10M and a timeline of 5-10 years. However, Persist AI claims it can reduce this time by 30-50% through its innovative use of automation and machine learning.
Founded in 2022, Persist AI operates in the intersecting industries of AI, Biotechnology, and Machine Learning, with its headquarters in the United States. The startup recently garnered a substantial $12.00M Series A investment, led by a diverse group of backers including 2048 Ventures, SignalFire, Spero Ventures, Y Combinator, Asymmetry Ventures, Eli Lilly, and others. This robust investor interest highlights the significant confidence in the company’s potential to disrupt traditional drug formulation processes.
